NASDAQ
Moleculin Biotech, Inc. (MBRX)
♥ 404 Thanks from members
Moleculin Biotech, Inc. (MBRX) faces severe downward momentum, highlighted by a wider-than-expected Q1 2026 net loss, a steep quarterly performance decline of over 70%, and an AI-driven Sell rating reflecting poor short-term market beating probabilities.